What You Ought to Know:
– Catalio Capital Management, LP (“Catalio”), a healthcare funding agency, at this time introduced the profitable shut of its fourth enterprise fund, Catalio Nexus Fund IV (“Fund IV”), with over $400M in commitments throughout the Fund and its associated co-investment autos.
– Launched in 2020 by Co-Founders George Petrocheilos and Dr. Jacob Vogelstein, Catalio presently manages $2B in property throughout its personal fairness, personal credit score, and public equities methods.
A Differentiated Funding Strategy in Healthcare
Catalio’s core funding strategy facilities on figuring out and supporting transformative healthcare corporations which might be spun out of main tutorial establishments and led by repeat founders with deep scientific experience. Their Nexus funds have invested in over 80 personal corporations for the reason that agency’s inception 5 years in the past. Catalio has additionally efficiently bought or taken public quite a lot of companies over time, constantly making distributions to its restricted companions yearly since its founding.
Fund IV’s Early Investments and Strategic Focus
To this point, Fund IV has already made 16 investments, showcasing Catalio’s dedication to partnering with world-class groups and constructing category-defining life sciences companies throughout all levels, from inception to IPO and past.
Latest highlights in Fund IV’s funding portfolio embody:
- Most cancers Diagnostics: Co-leading PinkDx’s $40 million Sequence A fundraise, targeted on creating diagnostics for gynecological cancers.
- AI-Enabled Drug Discovery: Investing within the Sequence A financing of Superluminal Medicines, increasing Catalio’s portfolio in AI-enabled drug discovery.
- New Firm Launches (Immunology & Irritation): Launching Rhapsogen, co-founded by Catalio Enterprise Companion Dr. Jeffrey Ravetch at Rockefeller College, and TBD Pharma, co-founded by Catalio Enterprise Companion Dr. Bert Vogelstein at Johns Hopkins College.
- Late-Stage Investments: Collaborating in Crucial Care’s $150M Sequence E financing (a medical system firm), a PIPE for Protara Therapeutics (an oncology firm), and Alentis Therapeutics’ $180M Sequence D financing (an organization creating antibody drug conjugates for oncology indications).
“We’re grateful for the continued confidence and powerful assist we obtained for Fund IV from each new and present excessive caliber buyers,” stated Olga Maltseva, Companion & Head of Operations at Catalio. “These new funds will permit Catalio to proceed making the most of alternatives in a historic purchaser’s market in biotech, and to maintain distinguishing ourselves as a number one modern healthcare investor across the globe.”
